发明名称 |
Stabilized Formulations Containing Anti-PCSK9 Antibodies |
摘要 |
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months. |
申请公布号 |
US2014341928(A1) |
申请公布日期 |
2014.11.20 |
申请号 |
US201414319730 |
申请日期 |
2014.06.30 |
申请人 |
Regeneron Pharmaceuticals, Inc. |
发明人 |
Walsh Scott M.;Dix Daniel B. |
分类号 |
C07K16/40;A61M5/315;A61M5/32 |
主分类号 |
C07K16/40 |
代理机构 |
|
代理人 |
|
主权项 |
1. A pre-filled syringe composition comprising a liquid pharmaceutical formulation, wherein the liquid pharmaceutical formulation comprises:
(a) 50±7.5 mg/mL to 250±37.5 mg/mL of an antibody or antigen-binding fragment thereof that specifically binds human proprotein convertase subtilisin kexin-9 (PCSK9), wherein the antibody comprises a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO:2, an HCDR2 of SEQ ID NO:3, an HCDR3 of SEQ ID NO:4, a light chain complementarity determining region (LCDR) 1 of SEQ ID NO:6, an LCDR2 of SEQ ID NO:7, and an LCDR3 of SEQ ID NO:8; (b) 10±1.5 mM histidine (pH 6.0±0.3); (c) 0.01±0.0015% w/v polysorbate 20; and (d) 10±1.5% sucrose;wherein said liquid pharmaceutical formulation is contained within a syringe. |
地址 |
Tarrytown NY US |